Serum carcinoembryonic antigen is associated with abdominal visceral fat accumulation in female Korean nonsmokers by �씠�뜒泥� et al.
Serum Carcinoembryonic Antigen Is Associated with
Abdominal Visceral Fat Accumulation in Female Korean
Nonsmokers
Jee-Yon Lee1, Hyang-Kyu Lee2, Duk-Chul Lee1, Ji-Won Lee1*
1Department of Family Medicine, Severance hospital, Yonsei University, College of Medicine, Seodaemun-gu, Korea, 2Department of Clinical Nursing Science, College of
Nursing, Yonsei, University, Seodaemun-gu, Korea
Abstract
Background: Carcinoembryonic antigen (CEA) is a tumor marker overexpressed in adenocarcinoma that has
proinflammatory properties. Recent studies have reported that CEA is positively associated with carotid atherosclerosis
and metabolic syndrome. Because visceral obesity is a known risk factor for cardiometabolic diseases, CEA may also be
associated with visceral adiposity. Therefore, we investigated the relationship between serum CEA concentration and
visceral obesity in female Korean nonsmokers.
Methods: A total of 270 Korean female nonsmokers were enrolled during their routine health check-ups. Biomarkers of
metabolic risk factors were assessed along with body composition by computed tomography. Serum CEA levels were
measured by using a chemiluminescence immunoassay analyzer.
Results: Serum CEA levels correlated with visceral fat area, fasting glucose, and triglyceride levels after adjusting for age and
BMI. The mean visceral fat area increased significantly with the increasing CEA tirtiles. In a step-wise multiple regression
analysis, age (b= 0.26, p,0.01) and visceral fat area (b= 0.19, p = 0.03) were identified as explanatory variables for serum
CEA level.
Conclusions: This study suggested that CEA may be a mediator that links metabolic disturbance and tumorigenesis in
visceral obesity. Further studies are required to better understand the clinical and pathophysiological significance of our
findings.
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Introduction
Obesity is a risk factor for cardiovascular disease [1], diabetes
mellitus [1], and neoplastic conditions [2]. Previous studies have
reported that obesity is positively associated with mortality due to
cardiovascular disease, diabetes mellitus, and certain cancers [3,4].
The precise mechanism by which obesity promotes these health
problems is not entirely clear; however, regional distribution of
adipose tissue is thought to be a contributing factor [5]. Visceral
adipose tissue is more metabolically active than subcutaneous
adipose tissue [6] and has a stronger relationship with cardiometa-
bolic risk factors including dyslipidemia [7], hyperinsulinemia [8],
and tumorigenesis. Although the role of visceral adipose tissue in
these diseases has not been fully elucidated, visceral adipocytes
secrete cytokines, growth factors, and adhesion molecules that
promote the development of obesity-related pathologic conditions
[9].
Carcinoembryonic antigen (CEA) is a 180- to 200-kDa
glycoprotein (10) that is a widely used tumor marker [10]. CEA
is overexpressed in adenocarcinoma, especially colorectal cancer
[11]. Its efficacy in monitoring recurrence after colorectal cancer
treatment has been demonstrated in numerous studies [12].
However, CEA is not considered effective as a marker for cancer
screening, because CEA levels increase with age and are elevated
in many nonneoplastic conditions including smoking, inflamma-
tory bowel disease, and chronic hepatitis [13–15]. Furthermore,
recent studies have reported a positive association between CEA
and cardiometabolic diseases including carotid atherosclerosis [16]
and metabolic syndrome [17]. Although CEA stimulates produc-
tion of proinflammatory cytokines and adhesion molecules during
the development of atherosclerosis, insulin resistance (IR),
tumorigenesis, and metastasis, the precise mechanism underlying
the relationship between CEA and cardiometabolic diseases
remains unclear.
Because visceral obesity is known to be a major risk factor for
atherosclerosis, IR, and malignancy, CEA may be associated with
visceral adiposity. However, no studies have evaluated this
relationship. Therefore we investigated the relationship between
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serum CEA concentration and visceral obesity in female Korean
nonsmokers.
Methods
Ethics Statement
All subjects participated in the study voluntarily, and written
informed consent was obtained from each participant. The study
complied with the Declaration of Helsinki and the institutional
review board of Yonsei University College of Medicine approved
this study.
Study sample
The study sample consisted of 352 Korean women who visited
the Health Promotion Center and the Department of Family
Medicine at Severance Hospital for routine health check-ups
between January 2011 and March 2012. From the 697 women, a
total of 352 women agreed to participate in the study, so the initial
participation rate was 50.5%. Of the 352 women who were
initially enrolled, 270 women met all inclusion criteria and were
ultimately included in the study analysis, while 82 women were
excluded from further analysis after medical history screening. We
excluded 12 women who were missing data for CEA concentra-
tions and abdominal visceral fat area, and 28 women who were
current or former smokers. We also excluded women with
underlying medical condition including a history of chronic liver
disease (n = 4), chronic renal disease (n = 7), coronary artery
occlusive disease (n = 3), chronic inflammatory disease (e.g.,
pancreatitis, COPD; n= 6) or cancer (n = 5). Women with
abnormal liver (n = 3) or kidney function (n = 2) were also
excluded. Abnormal liver function was defined as serum aspartate
aminotransferase or alanine aminotransferase concentrations
.100 IU/L. Abnormal kidney function was defined as serum
creatinine concentration .1.4 mg/dL. We also excluded women
using any medications that could affect cardiometabolic function
including anti-hypertensive medicine, oral hypoglycemic agents,
lipid lowering agents, anti-obesity drugs, and antidepres-
sants.(n = 12; Figure 1). A total of 270 women were included for
the final analysis.
Measurements
All subjects completed a questionnaire about lifestyle factors,
including cigarette smoking and alcohol consumption (defined as
drinking alcohol more frequently than once a week). Anthropo-
metric measurements were taken by a single well-trained
examiner. Blood pressure was measured in the sitting position
after a 10-minute resting period. Body mass index was calculated
as weight divided by height squared. Waist circumference was
measured at the umbilicus while the subject was standing.
Bioelectrical impedance analysis was used to estimate body fat
percentage using the InBody 520 (Biospace, Seoul, Korea).
Abdominal fat tissue areas were measured by computed tomog-
raphy (Tomoscan 350; Philips, Mahwah, NJ, USA) as described
previously [18]. Blood samples were collected after a 12-hour
overnight fast. We measured fasting glucose, high-sensitivity C-
reactive protein (hs-CRP), total cholesterol, triglyceride, and high-
density lipoprotein (HDL)-cholesterol levels by using an ADVIA
1650 chemistry system (Siemens Medical Solution, Tarrytown,
NY, USA). Low-density lipoprotein (LDL)-cholesterol levels were
calculated using the Friedewald equation. Fasting insulin was
determined by electrochemiluminescence immunoassay using an
Elecsys 2010 (Roche, Indianapolis, IN, USA). IR was estimated by
the homeostasis model assessment of insulin resistance (HOMA-
IR) index: (insulin [mIU/mL]6 fasting blood glucose [mg/dL]/
18)/22.5.
CEA was measured by a chemiluminescence immunoassay
(CLIA) using a DxI 800 Access Immunoassay System (Beckman
Coulter Inc., Brea, CA, USA). Assay precision was evaluated by
testing three control concentrations of commercially available
quality control materials (MAS T-Marker; Medical Analysis
Systems, Camarillo, CA, USA) and pooled human serum for the
respective markers. Each sample was assayed twice, in duplicate
each time, with a minimum of 2 hour intervals between runs. The
inter-assay and intra-assay coefficients of variations were
3.8061.96% and 3.0161.55% respectively.
The hypertension group was defined as subjects with systolic
BP$140 mmHg or diastolic BP$90 mmHg. The diabetes group
was defined as subjects with fasting blood glucose $126 mg/dL.
The dyslipidemia group was defined as subjects with hypercho-
lesterolemia (.240 mg/dL), hypertriglyceridemia (.150 mg/dL),
or low HDL-cholesterol (,50 mg/dL).
Statistical analysis
Normally distributed data are expressed as mean 6 standard
deviation (SD), and non-normally distributed data are expressed as
median and interquartile range. Pearson and Spearman correla-
Figure 1. Patient selection flow-chart for our study evaluating the association of CEA levels and visceral obesity.
doi:10.1371/journal.pone.0043518.g001
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tion analysis was performed to evaluate relationships between
CEA and other metabolic variables. The mean visceral fat area of
the participants according to the CEA tertiles was compared using
one-way ANOVA. Multiple linear regression analysis was used to
identify factors contributing to serum CEA levels. For this analysis,
variables with p,0.2 from univariate analysis and clinically
important variables including age, BMI, and subcutaneous fat area
were entered. To avoid multicollinearity, if there was significant
correlation (r.0.7) between two variables, only one variable was
selected and entered into the model.
We performed all statistical analysis using the Statistical Package
for the Social Sciences, version 18.0 (SPSS Inc., Chicago, IL,
USA). Statistic significance was defined as p,0.05.
Results
Table 1 shows the clinical characteristics of the 270 subjects and
the relationships between serum CEA level and other variables.
The mean age of subjects was 41.46614.0 years, and median
CEA level was 1.06 ng/mL(0.68–1.58). After adjusting for age and
BMI, CEA levels remained significantly correlated with visceral fat
area (r = 0.17 p= 0.01), fasting glucose (r = 0.17, p = 0.01), and
triglyceride levels (r = 0.13, p = 0.03). The mean CEA level was
significantly higher in hypertensive group (1.63 ng/mL) versus the
normotensive group (1.16 ng/mL; p,0.01), in diabetic group
(1.87 ng/mL) versus the non-diabetic group (1.18 ng/mL;
p,0.01) and in dyslipidemia group (1.58 ng/mL) versus the
non-dyslipidemia group (1.19 ng/mL; p= 0.02). There were no
significant differences in mean CEA levels between the alcohol
group 0.88 ng/mL and the non-alcohol group (1.25 ng/mL;
p= 0.28). (Data not shown)
Figure 2 and 3 shows the relationship between CEA and
abdominal adiposity. Serum CEA level correlated positively with
visceral fat area but not with subcutaneous fat area (Figure 2).
Figure 3 shows the mean visceral fat area according to the CEA
tertiles. (T1, ,0.9; T2, 0.9–1.4; T3.=1.4 ng/ml) Visceral fat
area increased continuously according to the CEA tertiles.
In a linear multiple regression analysis, age (b= 0.26, p,0.01)
and visceral fat area (b= 0.19, p= 0.03) were identified as
significant explanatory variables for serum CEA levels, accounting
for a combined 22% of the variance in CEA concentration.
(Table 2) The relationship between CEA level and visceral fat area
Table 1. Clinical characteristics of study subjects and the correlation between serum CEA levels and various metabolic parameters.
Variables Total (n = 270) r p-value Age, BMI adjusted
r p
CEA (ng/mL) 1.06 (0.68–1.58)
Age (years) 41.46614.00 0.43 ,0.01
Adiposity index
BMI (kg/m2) 27.2265.08 0.02 0.72
Waist (cm) 89.7269.58 0.06 0.33 0.04 0.48
Body fat (%) 36.4766.71 20.01 0.93 0.01 0.83
Visceral fat area (cm2) 98.79649.44 0.25 ,0.01 0.17 0.01
Subcutaneous fat area (cm2) 263.00692.66 20.02 0.75 0.00 0.99
Blood pressure (mmHg)
Systolic 120.00 (113.00–131.75) 0.11 0.08 0.02 0.78
Diastolic 74.2669.50 0.22 ,0.01 0.06 0.33
Fasting glucose (mg/dL) 91.00 (86.00–98.00) 0.24 0.01 0.17 0.01
Fasting insulin (mIU/mL) 8.17 (5.50–12.97) 0.13 0.03 0.05 0.44
HOMA-IR 1.88 (1.23–2.97) 20.07 0.26 0.09 0.16
Lipid profile (mg/dL)
Total cholesterol 187.56635.27 0.09 0.16 0.05 0.44
Triglyceride 92.50 (64.75–137.25) 0.18 ,0.01 0.13 0.03
HDL-cholesterol 52.58613.21 20.07 0.29 20.01 0.87
LDL-cholesterol 112.84631.64 0.05 0.45 0.00 0.93
hs-CRP (mg/L) 0.86 (0.48–1.88) 0.04 0.61 20.01 0.93
Hypertension, n (%) 50 (18.30%)
Diabetes, n (%) 22 (8.20%)
Dyslipidemia, n (%) 29 (10.60%)
Alcohol drinking, n (%) 10 (3.70%)
Note: BMI, body mass index; HOMA-IR; homeostasis model of assessment of insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hs-CRP, high-
sensitivity C-reactive protein.
Alcohol consumption was defined as consuming alcohol more frequently than once a week.
Data are expressed as mean (6SD) or percentage. Skewed data are expressed as median (range).
Coefficients(r) and p-values were calculated by the Pearson correlation model (normally distributed variables: age, BMI, waist circumference, subcutaneous fat area,
diastolic blood pressure, fasting glucose, total cholesterol, and LDL-cholesterol) or Spearman correlation model (non-normally distributed variables: body fat, visceral fat
area, systolic blood pressure, fasting insulin, HOMA-IR, triglycerides, HDL-cholesterol, and hs-CRP).
doi:10.1371/journal.pone.0043518.t001
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remained significant after exclusion of participants with hyperten-
sion (n = 50) and diabetes (n = 22) (b=0.36, r,0.01).
Discussion
Our cross-sectional study revealed a relationship between serum
CEA level and visceral obesity in female Korean nonsmokers. This
association remained significant after adjusting for BMI as an
overall marker of obesity, and for other confounding factors
related to metabolic syndrome including glucose, insulin, total
cholesterol, triglycerides, HDL-cholesterol, and blood pressure.
CEA is used to monitor disease recurrence and therapeutic
efficacy in colorectal cancer [19]. However, serum CEA levels are
also mildly elevated in several nonmalignant conditions [13–15],
including metabolic disturbances. Furthermore, Nobukarzu et al
[16] reported a positive relationship between carotid atheroscle-
rosis and serum CEA concentration. In our previous studies [17],
serum CEA was positively associated with metabolic syndrome in
a concentration-dependent manner. However, the relationship
between CEA and fat distribution is yet not well understood. This
is the first study to evaluate the relationship between serum CEA
levels and abdominal visceral obesity.
The precise underlying mechanisms that explain the relation-
ship between serum CEA concentration and visceral obesity
remain unclear. To our knowledge, there are no prior experi-
mental studies that evaluated the role of CEA in visceral adiposity.
Whether CEA levels and visceral fat amounts are directly
associated, or if this relationship is mediated by other environ-
mental factors, has not yet been figured out. Therefore, additional
basic experimental studies are warranted. However, we propose
two possible mechanisms.
First, if the association between CEA and visceral fat is
mediated by environmental factors, then inflammatory cytokines
and adipokines could be possible intermediary candidates. Adipose
tissues secrete various inflammatory cytokines and adipokines that
Figure 2. Relationship between abdominal visceral fat area, abdominal subcutaneous fat area, and serum CEA levels.
doi:10.1371/journal.pone.0043518.g002
Serum CEA Levels and Abdominal Visceral Fat
PLOS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e43518
induce the systemic chronic low-grade inflammatory status
observed in visceral obesity [20]. Altered adipokines and cytokines
in visceral obesity contribute to the development of IR, cardio-
metabolic disease, and malignancy [21–24]. Since CEA levels are
associated with diverse chronic inflammatory diseases [13,15],
increased inflammatory cytokines and adipokines in visceral
obesity may stimulate the cellular expression of CEA.
Second, direct association of CEA with visceral adiposity
without any mediators should be considered. It has been reported
that CEA can be secreted from non-CEA producing cells under
certain conditions [25,26]. Hence, we can hypothesize that
alteration of cellular environment in visceral obesity may induce
the direct expression of CEA from adipocytes. Basic experimental
studies are needed to elucidate the precise mechanistic association
between CEA and visceral obesity.
This study has several limitations. First, the cross-sectional
design cannot establish a causal relationship between CEA levels
and visceral obesity and also does not exclude the possibility that
CEA levels were elevated prior to visceral obesity. Second, we
enrolled only females; therefore, our results may not be
generalizable to men. Third, the small sample size of our study
is another limitation. Fourth, we used nonprobability sampling so
our results do not allow generalization of the results to the
population at large. Finally, although we considered a large
number of potentially confounding metabolic factors in our study,
evaluation of all potential confounding factors is impossible. We
agree that consideration of other potential confounders, including
assessing inflammatory cytokine and adipokine levels in study
subjects, will provide additional important information in future
studies.
In conclusion, our study showed that serum CEA is associated
with abdominal visceral obesity in female Korean nonsmokers.
Our findings collectively suggest that CEA may be a mediator that
links metabolic disturbance and tumorigenesis in visceral obesity.
In addition, elevation CEA, even within the ‘‘normal’’ range, may
be considered a detective marker for metabolic diseases related to
visceral obesity. Further studies are required to better understand
the clinical and pathophysiological significance of our findings.
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